Canaccord said Meridian Bioscience's preannounced second quarter top-line miss and expected ongoing weakness in its MDx business were among the reasons for the downgrade.
UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.
The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.
The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.
The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.
Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.
In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.
